Breaking News
Investing Pro 0
New Year’s SALE: Up to 40% OFF InvestingPro+ CLAIM OFFER

Biogen gains as analysts raise numbers after Roche's gantenerumab failure

Stock Markets Nov 14, 2022 08:16
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters
 
LLY
-0.47%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
BIIB
-1.43%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
RHHBY
-0.97%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

By Senad Karaahmetovioc

Biogen (NASDAQ:BIIB) shares are trading more than 5% higher in pre-market Monday after rival Roche (OTC:RHHBY) presented disappointing results for its Alzheimer’s treatment gantenerumab.

Much-awaited results showed gantenerumab failed its phase 3 trial. While the drug was well tolerated, the level of beta-amyloid was lower than expected.

RBC analysts believe the trial results “remove a competitor which could have had an advantage of a more convenient formulation.”

“We think that it also raises a slight risk as lecanemab is the only drug that has worked so far by targeting the amyloid pathway, and we think FDA may add more scrutiny to the Ph.III data from the CLARITY AD to understand why the study worked,” the analysts said in a client note.

Stifel analysts are more positive as they raised the price target on Biogen to $331 per share, up from the prior $299 after removing any share from Roche's gantenerumab in their Alzheimer's market model.

“We believe the gant failure further increases the likelihood that lecanemab--on the back of strong efficacy data and best-in-class safety data--could be the leading anti-amyloid therapy within a $10B+ market,” they wrote in a note.

Wolfe analysts added that the trial failure is a boost for Biogen and Eli Lilly (NYSE:LLY). For Roche, this is a clear setback although “not one that was totally unexpected.”

At 08:00 ET (13:00 GMT), Roche (SIX:RO) shares are down 4.5% in European trading. LLY shares are up about 1.8% in U.S. pre-market trading.

 
 
Biogen gains as analysts raise numbers after Roche's gantenerumab failure
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email